{"id":"abobotulinumtoxina-dose-level-1-or-2","safety":{"commonSideEffects":[{"rate":"null","effect":"Eyelid ptosis"},{"rate":"null","effect":"Diplopia"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Injection site pain"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2108570","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by blocking the release of acetylcholine, a neurotransmitter that signals muscle contractions. This results in a reduction in muscle spasms and contractions. AbobotulinumtoxinA is used to treat a variety of conditions, including facial wrinkles and muscle spasms.","oneSentence":"AbobotulinumtoxinA is a botulinum toxin type A that works by temporarily paralyzing muscle contractions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:23.124Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glabellar lines"},{"name":"Frown lines"},{"name":"Cervical dystonia"},{"name":"Axillary hyperhidrosis"}]},"trialDetails":[{"nctId":"NCT07489430","phase":"PHASE2","title":"DaxibotulinumtoxinA for Blepharospasm","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-07-01","conditions":"Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid, Blepharospasm of Right Eyelid","enrollment":20},{"nctId":"NCT04752774","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.","status":"RECRUITING","sponsor":"Ipsen","startDate":"2021-04-29","conditions":"Spasticity","enrollment":240},{"nctId":"NCT07360483","phase":"NA","title":"Treatment of Hypertrophic Scars Using Fractional CO2 Laser Alone in Comparison With Adding Botulinum Toxin Either Through Intralesional Injection or Assisted Drug Delivery","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-01-01","conditions":"Hypertrophic Scars","enrollment":48},{"nctId":"NCT02816151","phase":"PHASE3","title":"Children Toxine Botulinum Detrusor Injection in Neurogenic Vesical Hyperactivity Syndrom: Non Inferiority Multicenter Controlled Therapeutic Study Between Two Reported Weight's Doses","status":"COMPLETED","sponsor":"CHU de Reims","startDate":"2011-02","conditions":"Neurogenic Vesical Hyperactivity Syndrom","enrollment":29},{"nctId":"NCT07270042","phase":"NA","title":"Evaluation the Efficacy of Zinc on Botulinum Toxin A Injection","status":"NOT_YET_RECRUITING","sponsor":"Tishreen University","startDate":"2025-12-01","conditions":"Hyperactive Masseter Muscle","enrollment":20},{"nctId":"NCT06137287","phase":"PHASE3","title":"A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-11-22","conditions":"Masseter Muscle Prominence","enrollment":259},{"nctId":"NCT05874154","phase":"NA","title":"Evaluation of Tibial Nerve Selective Neurotomy Compared to Botulinum Toxin Injections for Spastic Foot Treatment in Post-stroke Patients According to a Goal-centered Approach","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-01-02","conditions":"Post Stroke Seizure, Spastic Foot","enrollment":60},{"nctId":"NCT03654066","phase":"PHASE4","title":"Botox or Botox With Esophageal Dilation in Patients With Achalasia","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2019-05-13","conditions":"Achalasia","enrollment":50},{"nctId":"NCT06886750","phase":"PHASE4","title":"The Effects of Waning of Botulinum Toxin in the Treatment of Cervical Dystonia","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2025-03-30","conditions":"Cervical Dystonia, Primary","enrollment":45},{"nctId":"NCT02969356","phase":"PHASE4","title":"Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)","status":"COMPLETED","sponsor":"Ipsen","startDate":"2016-12-18","conditions":"Spastic Hemiparesis","enrollment":157},{"nctId":"NCT05072821","phase":"PHASE4","title":"Botulinum Toxin Type a Injection to Prevent Keloid Recurrence","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-10-13","conditions":"Scar Keloid","enrollment":28},{"nctId":"NCT04819360","phase":"PHASE4","title":"Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis","status":"TERMINATED","sponsor":"Brigitte Schürch","startDate":"2021-06-01","conditions":"Urinary Bladder, Neurogenic, Multiple Sclerosis","enrollment":1},{"nctId":"NCT05426161","phase":"PHASE4","title":"The Effect of Subcutaneous Injection of Botulinum Toxin A on Chronic Wound Pain in Lower Extremities","status":"COMPLETED","sponsor":"Bispebjerg Hospital","startDate":"2023-02-07","conditions":"Chronic Pain, Lower Extremity Wound","enrollment":10},{"nctId":"NCT06230146","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Fractional CO2 Laser Combined With Intralesional Insulin, Botulinum Toxin or Triamcinolone Acetonide in the Treatment of Keloid: A Clinical, Dermoscopic and Immunohistochemical Study.","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-05-01","conditions":"Keloid","enrollment":45},{"nctId":"NCT05719285","phase":"PHASE4","title":"Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2022-12-06","conditions":"Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence","enrollment":100},{"nctId":"NCT03712449","phase":"PHASE4","title":"A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment","status":"COMPLETED","sponsor":"Allergan","startDate":"2019-01-22","conditions":"Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality","enrollment":59},{"nctId":"NCT03911102","phase":"PHASE2","title":"Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2019-03-11","conditions":"Lateral Canthal Lines","enrollment":63},{"nctId":"NCT05617118","phase":"","title":"BTA vs Baclofen for Pelvic Myofascial Pain Syndrome","status":"UNKNOWN","sponsor":"Saint Petersburg State University, Russia","startDate":"2022-12-01","conditions":"Chronic Pain, Chronic Pelvic Pain Syndrome, Myofascial Pain Syndrome","enrollment":52},{"nctId":"NCT02097121","phase":"PHASE3","title":"OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)","status":"TERMINATED","sponsor":"Allergan","startDate":"2014-05-23","conditions":"Urinary Incontinence, Urinary Bladder, Overactive","enrollment":56},{"nctId":"NCT01251380","phase":"PHASE3","title":"Dysport® Pediatric Lower Limb Spasticity Follow-on Study","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-10","conditions":"Cerebral Palsy, Muscle Spasticity, Children","enrollment":216},{"nctId":"NCT01313312","phase":"PHASE3","title":"Dysport® Adult Upper Limb Spasticity Extension Study","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-11","conditions":"Nervous System Disorders","enrollment":258},{"nctId":"NCT03736928","phase":"PHASE2","title":"Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2018-11-26","conditions":"Glabellar Frown Lines","enrollment":401},{"nctId":"NCT05340439","phase":"PHASE2","title":"INcobotulinumtoxina in ChIldren Upper and Lower Limb sPasticITy (INCIPIT)","status":"UNKNOWN","sponsor":"Universita di Verona","startDate":"2022-06","conditions":"Spastic Cerebral Palsy","enrollment":30},{"nctId":"NCT03598777","phase":"PHASE2","title":"Dysport in Vulvodynia Phase II Study","status":"TERMINATED","sponsor":"Ipsen","startDate":"2018-06-11","conditions":"Vulvodynia","enrollment":60},{"nctId":"NCT03663101","phase":"PHASE2","title":"Dysport in Post-Surgical Neuralgia","status":"COMPLETED","sponsor":"Ipsen","startDate":"2018-10-30","conditions":"Chronic Scar Pain","enrollment":16},{"nctId":"NCT04305743","phase":"PHASE4","title":"Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A","status":"RECRUITING","sponsor":"University of South Florida","startDate":"2019-10-09","conditions":"Urinary Bladder, Overactive, Incontinence, Urge, Incontinence, Urinary","enrollment":60},{"nctId":"NCT01032954","phase":"PHASE4","title":"Safety and Efficacy of the Full Face Applications of Variable Doses of a Commercial Botulinum Toxin Type a (Dysport®)","status":"COMPLETED","sponsor":"Hexsel Dermatology Clinic","startDate":"2009-11","conditions":"Sun-induced Wrinkles","enrollment":90},{"nctId":"NCT03796351","phase":"PHASE1","title":"Pharmacodynamic and Safety of MT10107(Botulinum Type A Neurotoxin) in Comparison to BOTOX®","status":"COMPLETED","sponsor":"Medy-Tox","startDate":"2012-09","conditions":"Healthy Volunteers","enrollment":25},{"nctId":"NCT01700387","phase":"PHASE4","title":"A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency","status":"COMPLETED","sponsor":"Cady, Roger, M.D.","startDate":"2012-10","conditions":"Chronic Migraine","enrollment":20},{"nctId":"NCT03837561","phase":"PHASE3","title":"The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Medy-Tox","startDate":"2018-12-13","conditions":"Glabellar Frown Lines","enrollment":136},{"nctId":"NCT02298660","phase":"PHASE4","title":"Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI","status":"COMPLETED","sponsor":"Rick Hansen Institute","startDate":"2013-04","conditions":"Autonomic Dysreflexia","enrollment":55},{"nctId":"NCT01603615","phase":"PHASE3","title":"BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-10-30","conditions":"Pediatrics, Muscle Spasticity, Cerebral Palsy","enrollment":220},{"nctId":"NCT01603641","phase":"PHASE3","title":"BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-11-05","conditions":"Pediatrics, Muscle Spasticity, Cerebral Palsy","enrollment":370},{"nctId":"NCT03496649","phase":"PHASE2","title":"Pubalgia and Adductor Tendinopathies Refractory to Medical Treatment","status":"UNKNOWN","sponsor":"University Hospital, Bordeaux","startDate":"2019-05-02","conditions":"Groin Injury, Tendinopathy","enrollment":20},{"nctId":"NCT01767519","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-03-01","conditions":"Overactive Bladder, Urinary Incontinence","enrollment":356},{"nctId":"NCT03891121","phase":"NA","title":"Occlusal Splints or Botulinum Toxin?","status":"COMPLETED","sponsor":"Ankara University","startDate":"2018-04-05","conditions":"Myofascial Pain, Temporomandibular Disorder","enrollment":73},{"nctId":"NCT02618889","phase":"PHASE4","title":"OnabotulinumtoxinA in the Management of Psychogenic Dystonia","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2016-01-15","conditions":"Torticollis, Dystonia","enrollment":18},{"nctId":"NCT03616262","phase":"EARLY_PHASE1","title":"\"Efficacy of Botulinum Toxin Injection in Reducing Limb Pain in Patients With Complex Regional Pain Syndrome\"","status":"UNKNOWN","sponsor":"VA Connecticut Healthcare System","startDate":"2016-07","conditions":"Complex Regional Pain Syndrome","enrollment":20},{"nctId":"NCT02091739","phase":"PHASE3","title":"Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2014-04","conditions":"Chronic Troublesome Sialorrhea, Parkinson's Disease, Post-stroke","enrollment":184},{"nctId":"NCT02472210","phase":"PHASE4","title":"The Use of Botox in Advanced Parkinson's Patients Experiencing Pain","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2014-07","conditions":"Parkinson's Disease","enrollment":14},{"nctId":"NCT02425176","phase":"PHASE2, PHASE3","title":"Botulinum Toxin-A for Sialorrhoea Treatment in Asian Adults With Neurological Diseases","status":"COMPLETED","sponsor":"University of Malaya","startDate":"2009-09","conditions":"Sialorrhea","enrollment":30},{"nctId":"NCT00819065","phase":"PHASE3","title":"Trial Comparing Two Commercial Formulations of Botulinum Toxin Type A in the Treatment of Spasticity","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2009-03","conditions":"Spasticity","enrollment":56},{"nctId":"NCT00989768","phase":"PHASE4","title":"Field of Effects of Two Commercial Preparations of Botulinum Toxin Type A","status":"COMPLETED","sponsor":"Hexsel Dermatology Clinic","startDate":"2005-05","conditions":"Wrinkles in Frontal Area","enrollment":29},{"nctId":"NCT00682760","phase":"PHASE3","title":"Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm","status":"COMPLETED","sponsor":"Pacific Pharmaceuticals","startDate":"2005-10","conditions":"Blepharospasm","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9977262,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AbobotulinumtoxinA dose level 1 or 2","genericName":"AbobotulinumtoxinA dose level 1 or 2","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Biologic","firstApprovalDate":"","aiSummary":"AbobotulinumtoxinA is a botulinum toxin type A that works by temporarily paralyzing muscle contractions. Used for Glabellar lines, Frown lines, Cervical dystonia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}